Assessment of Myocardial Blood Flow and Cardiac FDG Uptake Using Positron Emission Tomography

The 17^th Society Award of Japanese Society of Nuclear Cardiology

抄録

Cardiac positron emission tomography (PET) has evolved over the several decades since its introduction. In current clinical practice and research, cardiac PET imaging is accepted as a valuable noninvasive modality for assessing various cardiac diseases such as coronary artery disease (CAD), cardiac tumors, and inflammatory diseases including cardiac sarcoidosis (CS). PET enables the imaging and evaluation of the cardiovascular system by myocardial perfusion with ⁸²Rb, ¹³N-NH₃ and ¹⁵O-H₂O, and those of metabolism and inflammation using ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG). PET has demonstrated superior diagnostic accuracy for the detection of CAD and also has well-established prognostic value. The combination of qualitative and absolute quantifications of myocardial blood flow enhances the diagnostic accuracy for multiple-vessel disease and provides incremental functional and prognostic information. In this review, we focus on the current and future roles of cardiac PET imaging, on the basis of our own experience.